Login to Your Account



In The Clinic NEWS
TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.
Spectrum Pharmaceuticals Inc. looked toward another win in its late-stage pipeline as Captisol-enabled (propylene glycol-free) melphalan met the primary endpoints in a pivotal phase II safety and efficacy study.

Evoke Pharma Inc. enrolled the first patient in the phase III trial of EVK-001, its intranasal formulation of metoclopramide, to treat symptoms associated with acute and recurrent diabetic gastroparesis in women.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: